Real Option Approach for the Management of a New Product Development in the Pharmaceutical Sector

Abstract:

The main scope of this paper is to perform a real options analysis that is often recommended as an emerging valuation technique for high-risk investment projects. The pharmaceutical sector is a sector where the real option can be positively applied to incorporate the flexibility and the risks of the new product development. In this paper the real option theory is applied to a pharmaceutical company that is developing a particular new product. Due to the uncertain nature of the new product development, it can be strategic to evaluate the real option benefits for the investment under analysis.

• Periodical: Advanced Materials Research (Volume 746)
• Pages: 551-556
• DOI: https://doi.org/10.4028/www.scientific.net/AMR.746.551
• Online since: August 2013
• Authors: Federica Cucchiella, Massimo Gastaldi
• Keywords: Net Present Value, New Pharmaceutical Product Development, Real Option

References

[1] M.J. Higgins and D. Rodriguez, The outsourcing of R&D through acquisition in the pharmaceutical industry, Journal of Financial Economics, 80 (2006), pp.351-383.

[2] M. Hartmann and A. Hassan, Application of real options analysis for pharmaceutical R&D project valuation - Empirical results from a survey, Research Policy, 35(3) (2006) pp.343-354.

DOI: 10.1016/j.respol.2005.12.005

[3] F. Cucchiella, M. Gastaldi and S.C.L. Koh, Performance improvement: an active life cycle product management, International Journal of Systems Science, 41 (2010) pp.301-313.

DOI: 10.1080/00207720903326886

[4] K. Rocha, L. Salles, F.A. Alcaraz Garcia, J.A. Sardinha and J.P. Teixeira, Real estate and real options — A case study, Emerging Markets Review, 8 (2007) p.67–79.

DOI: 10.1016/j.ememar.2006.09.008

[5] M. Benaroch, S. Shah and M. Jeffery, On the Valuation of Multistage Information Technology Investments Embedding Nested Real Options, Journal of Management Information Systems, 23(1) (2006) pp.239-261.

DOI: 10.2753/mis0742-1222230108

[6] F. Cucchiella and M. Gastaldi, Risk management in supply chain: a real option approach, Journal of Manufacturing Technology Management - special issue, 17(6) (2006), pp.700-720.

DOI: 10.1108/17410380610678756

[7] L. Trigeorgis, Real Options: Managerial Flexibility and Strategy in Resource Allocation, Cambridge, MA, MIT Press (1996).

[8] N. Kulatilaka, The value of flexibility: A general model of real options, in Real Options in Capital Investment: Models, Strategies, and Application (Ed, Trigeorgis, L. ) Praeger (2006).

[9] S. Ogawa and F.T. Piller, Reducing the Risks of New Product Developmet, MIT Sloan Management Review, 47 (2006), pp.65-71.

[10] F. Cucchiella, I. D'Adamo, M. Gastaldi and S.C.L. Koh, Implementation of a real option in a sustainable supply chain: an empirical study of alkaline battery recycling, The International Journal of Systems Science, doi: 10. 1080/00207721. 2012. 761458, in press.

DOI: 10.1080/00207721.2012.761458

[11] M.J. Rogers, A. Gupta and C.D. Maranas, Real Options Based Analysis of Optimal Pharmaceutical Research and Development Portfolios, (Ed, ACS Publications) Department of Chemical Engineering, The Pennsylvania State University, University Park, Pennsylvania (2002).

DOI: 10.1021/ie020385p

[12] A. Calabrese, M. Gastaldi and N.L. Ghiron, Real option's model to evaluate infrastructure flexibility: an application to photovoltaic technology, International Journal of Technology Management, 29 (2005), pp.173-191.

DOI: 10.1504/ijtm.2005.006014

[13] F. Cucchiella and M. Gastaldi, Development of new product in pharmaceutical sector: a real option risk management, CD Proceedings of the Ninth International Conference on Production Engineering, Design and Control, Alexandria (Egypt), (2009).